Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
Stock Information for NanoViricides Inc.
Loading
Please wait while we load your information from QuoteMedia.